Casey Ikemire
Primary Care · Mount Carmel, ILNPI 1104426428
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations.
Across 166 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$402
- Novo Nordisk$315
- Mylan Specialty L.p.$173
- GSK$168
- Harmony Biosciences LLC$158
- Lilly USA, LLC$157
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,520100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,520 in reported general payments places this provider in the 80th percentile of 150 primary care providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $22,253 |
| MounjaroTirzepatide | 21 | $20,861 |
| RybelsusSemaglutide | 21 | $20,416 |
| OzempicSemaglutide | 16 | $15,043 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $13,859 |
| TrulicityDulaglutide | 13 | $12,227 |
| LinzessLinaclotide | 19 | $9,855 |
| JardianceEmpagliflozin | 12 | $7,479 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,389 |
| Metoprolol Succinate | 64 | $1,188 |
| Levothyroxine Sodium | 82 | $744 |
| Memantine Hcl ErMemantine Hcl | 11 | $526 |
| Divalproex Sodium | 12 | $526 |
| Sucralfate | 14 | $524 |
| Atorvastatin Calcium | 79 | $487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $315 | $35,45937 claims |
| Lilly USA, LLCMounjaro, Trulicity | $157 | $33,08834 claims |
| PfizerEliquis | $82 | $22,25327 claims |
| GSKTrelegy Ellipta | $168 | $13,85922 claims |
| AbbVieLinzess | $402 | $9,85519 claims |
| Boehringer IngelheimJardiance | $24 | $7,47912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 150 primary care providers in Illinois.
Other primary care in Mount Carmel
- Nicole LorangElk Grove Village$19K
- Allison LindstromChicago$15K
- Rachel ProkopfOak Park$13K
- Dawn ConwayChicago$11K
- Anne MaynardGlen Ellyn$9K
- Megan McLuckieHoffman Estates$9K
- Megan NiemiecNew Lenox$7K
- Ashley CarterChicago$7K
- Blake WoodsMetropolis$6K
- Jennifer VazquezChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.